SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™
SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™
Applications:
FC
Cookie Settings
We use cookies to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement and Cookie Statement.
Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. | |
A) Unstimulated cells |
 View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |  View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
B) Cells stimulated with PepTivator® SARS-CoV-2 Prot_N | |
 View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |  View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
C) Cells stimulated with PepTivator® SARS-CoV-2 Prot_S1 | |
 View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |  View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. | |
A) Unstimulated cells |
View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. | View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
B) Cells stimulated with PepTivator® SARS-CoV-2 Prot_N | |
View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. | View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
C) Cells stimulated with PepTivator® SARS-CoV-2 Prot_S1 | |
View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. | View details SARS-CoV-2 T Cell Analysis Kit (Whole Blood), anti-human, REAfinity™Figure 2Human whole blood (1 mL) from SARS-CoV-2–reactive donors were incubated for 8 hours with Brefeldin A. Simultaneously, cells were either left unstimulated (A) or incubated with a selection of SARS-CoV-2 PepTivators Prot_N (130-126-700) (B) or Prot_S1 (130-127-041) (C). Blood samples were lysed and then fixed and permeabilized afterwards. Subsequently, cells were stained with the flow panel included in this kit. Cells were analyzed using a MACSQuant ® Analyzer 16. Doublets, debris, and dead cells as well as CD14 + and CD20 + cells were excluded. After pregating on CD3 as well as CD4 and CD8, respectively, activation marker and cytokine expression were assessed, e.g. CD154 and IL-2 for CD4 + T cells and TNF-α and IFN-γ for CD8 + T cells. |
Seems like you are coming from USA!
Do you want to visit our website in your country?
Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.
